Background {#Sec1}
==========

Despite significant advances in the treatment of non-small-cell lung cancer (NSCLC) over the last two decades, the results of standard chemotherapy for advanced NSCLC have reached a plateau and new treatment strategies are necessary. The introduction of epidermal growth factor receptor (EGFR) inhibitors was considered a promising strategy. EGFR-tyrosine-kinase inhibitors (TKIs), specifically gefitinib and erlotinib, are currently considered the standard first-line treatment for patients with activating EGFR mutations based on the results of several randomized studies \[[@CR1]--[@CR6]\]. However, the benefit of these agents is confined to patients with EGFR mutation \[[@CR7], [@CR8]\].

The mechanism of action of EGFR inhibitors is the inhibition of tumor cell proliferation and induction of apoptosis. The addition of EGFR inhibitors to standard chemotherapy is an attractive approach to enhance its efficacy. However, no survival advantage was detected in trials such as the INTACT I, II, and TRIBUTE studies \[[@CR9]--[@CR11]\]. One possible explanation for the failure of these studies is that tumor cells that were driven to G0/G1 phase by EGFR TKIs may not be sensitive to cytotoxic chemotherapy. Preclinical studies and several phase 1 and 2 studies showed that sequential treatment with chemotherapy followed by EGFR TKIs led to synergistic cytotoxicity \[[@CR12]--[@CR16]\].

The present study examined the effect of gefitinib administered for 2 weeks after paclitaxel and carboplatin (PC) chemotherapy by assessing cell-cycle progression during chemotherapy in patients with NSCLC. Non-smoking patients with adenocarcinoma and patients with mutant EGFR, who were expected to benefit from gefitinib alone, were excluded from the analysis.

Methods {#Sec2}
=======

Study design and population {#Sec3}
---------------------------

This study was a single-center, prospective, open-label, randomized phase II study of paclitaxel and carboplatin with intercalated gefitinib (PCG) or PC alone (PC) for advanced NSCLC in a selected population of smokers with wild-type EGFR.

Patients were eligible for this study if they were 18 years or older, had a histological diagnosis of NSCLC with metastasis (stage IV) or locally advanced (stage IIIB) disease with malignant pleural effusion according to the 6th edition of the American Joint Committee on Cancer staging system. Inclusion criteria were ≥ 1 measurable lesion meeting Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) guidelines, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0--2, at least 1 week since the last radiotherapy session, and adequate organ function.

Exclusion criteria included tumors harboring EGFR mutation, prior systemic chemotherapy for NSCLC, non-smoking patients with adenocarcinoma (except patients with wild-type EGFR), symptomatic brain metastasis and any unstable medical condition.

This study was approved by the institutional review board of Asan Medical Center and was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients gave written informed consent before treatment. This study has been submitted for registration with ClinicalTrials.gov identifier NCT01196234.

Randomization {#Sec4}
-------------

Eligible patients were randomly assigned in a 1:1 ratio to receive PCG or PC alone. Randomization was stratified by gender and histology (adenocarcinoma, others).

Treatment plan {#Sec5}
--------------

Patients in the PCG arm received paclitaxel 175 mg/m^2^ and carboplatin AUC 5 intravenously on day 1 with intercalated gefitinib 250 mg orally once daily from day 2 through day 15 every 3 weeks for four cycles followed by gefitinib 250 mg orally until progressive disease or unacceptable toxicity. Patients in the PC arm received paclitaxel 175 mg/m^2^ and carboplatin AUC 5 intravenously on day 1 every 3 weeks until progressive disease up to four cycles without following maintenance therapy.

Dose adjustments were based on drug-related toxicities. When dose reduction was necessary, gefitinib was stopped every third day. If a patient still required dose reduction, it was stopped every other day. Any patient who required three dose reductions or developed interstitial lung disease (ILD) was discontinued from the study drug. Treatment could be delayed for a maximum of 2 weeks.

Evaluation {#Sec6}
----------

Physical examination, ECOG PS evaluation and toxicity rating according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0) were performed at baseline, prior to each cycle, and approximately 1 month after the last dose of the study drug. Tumor response was assessed by computed tomography (CT) with RECIST version 1.1 every 6 weeks during chemotherapy, and every 12 weeks thereafter until disease progression.

Statistical considerations {#Sec7}
--------------------------

The aim of this randomized phase II study was to assess the benefit of gefitinib intercalation with PC chemotherapy. The primary endpoint was objective response rate (ORR); complete response, (CR) or partial response, (PR). When the usual ORR in the PC chemotherapy arm was 40 % and an absolute increase of 15 % in the ORR was obtained by intercalation of gefitinib to standard PC chemotherapy in each arm of 37 patients, the probability of correctly selecting PC chemotherapy with gefitinib as superior was 0.9. Considering follow-up loss, 42 patients were planned to be enrolled in each arm \[[@CR17]\].

ORR was analyzed using the *χ*2 test and data were expressed with 95 % confidence interval (CI). The secondary endpoints were progression-free survival (PFS) and overall survival (OS), which were assessed using the Kaplan-Meier method with hazard ratio (HR) and 95 % CI via Cox's proportional hazard model.

Results {#Sec8}
=======

Between April 2010 and December 2011, 90 patients were enrolled into the study and randomly assigned to receive PC with gefitinib (*N* = 44) or PC alone (*N* = 46). Finally, 43 patients in the PCG arm and 43 patients in the PC arm received at least one cycle of treatment (Fig. [1](#Fig1){ref-type="fig"}). Baseline characteristics were well balanced across the treatment arms (Table [1](#Tab1){ref-type="table"}). Median age was 60 (range, 44--72) years in the PCG arm and 59 (range, 37--70) years in the PC arm. Approximately 10 % of patients were non-smokers and 63 % had adenocarcinoma. Patients with stage IV cancer comprised about 80 % of each group equally.Fig. 1Trial profileTable 1Baseline characteristics of patients (intention to treat population)ParameterChemotherapy-gefitinib (PCG) (*N* = 44) (%)Chemotherapy (PC) (*N* = 46) (%)Total (*N* = 90) (%)*P*-valueAge (years) Median (range)60.0 (44--72)59.0 (37--70)59.5 (37--72)0.678Gender Male35 (79.5)42 (91.3)77 (85.6) Female9 (20.5)4 (8.7)13 (14.4)0.113Smoking status Smoker37 (84.1)44 (95.7)81 (90.0) Non-smoker7 (15.9)2 (4.3)9 (10.0)0.087ECOG status ECOG 0000 ECOG 144 (100)46 (100)90 (100)--Histological subtype Adenocarcinoma24 (54.5)31 (67.4)55 (61.1) Non-adenocarcinoma20 (45.5)15 (32.6)35 (38.9)0.211EGFR mutation Wild-type6 (13.6)3 (6.5)9 (10.0) Unknown38 (86.4)43 (93.5)81 (90.0)0.157Stage of disease Stage IIIB8 (18.2)10 (21.7)18 (20.0) Stage IV36 (81.8)36 (78.3)72 (80.0)0.673

Primary efficacy measures {#Sec9}
-------------------------

No significant difference in ORR was observed between the two arms (*P* = 0.826), with an ORR of 41.9 % (95 % CI: 27.0--57.9 %) for the PCG arm and 39.5 % (95 % CI: 25.0--55.6 %) for the PC arm (Table [2](#Tab2){ref-type="table"}). No difference in disease control rate (DCR) was observed between the two arms, with DCR values of 74.4 % (95 % CI: 58.8--86.5 %) and 65.1 % (95 % CI: 49.1--79.0 %), respectively (*P* = 0.348) (Table [2](#Tab2){ref-type="table"}).Table 2Best overall response according to RECISTParameterPCG arm (%) (*N* = 43)PC arm (%) (*N* = 43)Odds ratio (95 % CI)*P*-valueObjective response18 (41.9)17 (39.5)0.910.82695 % CI(27.0--57.9)(25.0--55.6)(0.38--2.13)Disease control32 (74.4)28 (65.1)0.640.34895 % CI(58.8--86.5)(49.1--79.0)(0.25--1.61)Complete response0 (0)0 (0)Partial response18 (41.9)17 (39.5)Stable disease14 (32.6)11 (25.6)Progressive disease10 (23.3)13 (30.2)Missing1 (2.3)2 (4.7)*N* number; *CI* confidence interval

Secondary efficacy measures {#Sec10}
---------------------------

During a median follow-up of 21.7 months, there were 83 patients with PFS events (disease progression or death from any cause). No statistically significant difference in PFS was found between the two arms (HR = 0.94 \[95 % CI: 0.61--1.45\], *P* = 0.781). Median PFS was 4.1 (95 % CI: 3.9--4.3) months in the PCG arm and 4.1 (95 % CI: 3.9--4.3) months in the PC arm (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Kaplan-Meier graph of progression-free survival by treatment group (ITT population)

A total of 66 patients had an OS event (death). No statistically significant difference in OS was observed between the groups (HR = 0.95 \[95 % CI: 0.58--1.54\], *P* = 0.827). Median OS was 9.3 (95 % CI: 7.0--11.6) months in the PCG arm and 10.5 (95 % CI: 8.3--12.7) months in the PC arm (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Kaplan-Meier graph of overall survival by treatment group (ITT population)

Exploratory analyses {#Sec11}
--------------------

Exploratory subgroup analyses are shown in Fig. [4](#Fig4){ref-type="fig"}. The negative result for the comparison between the PCG arm and the PC arm was generally consistent throughout all clinical subsets, although the small number of patients in several subsets resulted in large CIs and made the results difficult to interpret.Fig. 4Forest plots by clinical subgroups. yrs, years; adeno, adenocarcinoma

Safety {#Sec12}
------

Of the 90 patients, 86 received at least one dose of treatment and were included in the safety analyses. The median number of cycles received in both arms was 4.0.

The two arms showed a similar incidence of drug-related toxicity. Most AEs were clinically manageable. The most commonly reported AEs of any grade were anemia, neutropenia, rash, pruritus, myalgia, neuropathy, anorexia, and cough (Table [3](#Tab3){ref-type="table"}). Skin rash and pruritus were more common in the PCG arm (63 and 37 %) than in the PC arm (5 and 9 %), although no grade 3 rash or pruritus was observed in the PCG arm (Table [3](#Tab3){ref-type="table"}). Frequency of diarrhea was similar in both treatment groups (Table [3](#Tab3){ref-type="table"}). Twenty-two patients had at least one serious adverse event with CTCAE grade 3/4 \[10 in the PCG arm (23.3 %) and 12 in the PC arm (27.9 %)\] (Table [3](#Tab3){ref-type="table"}). Three patients died during the study period, two in the PCG arm (both from infection) and one in the PC arm (from pulmonary thromboembolism).Table 3Summary of the most common adverse eventsPCG arm (*N* = 43) (%)PC arm (*N* = 43) (%)*P*-value for all grade AEAll gradeGr 3Gr 4Gr 5All gradeGr 3Gr 4Gr 5Patients with ≥ 1 AE (Gr3/4/5)10 (23)12 (28)0.244^a^Rash27 (63)2 (5)\<0.001^a^Pruritis13 (37)4 (9)0.012Myalgia25 (58)28 (65)0.506Neuropathy21 (49)25 (58)0.387Alopecia24 (56)21 (49)0.517Anorexia15 (35)18 (42)0.506Cough16 (37)11 (26)0.245Nausea13 (30)8 (19)0.209Fatigue10 (23)10 (23)1.000Dyspepsia6 (14)7 (16)0.763Constipation6 (14)6 (14)1.000Diarrhea5 (12)5 (12)1 (2)1.000Chest pain5 (12)5 (12)1.000General weakness5 (12)1 (2)5 (12)1.000Infection6 (14)4 (9)2 (5)3 (7)3 (7)0.483TE event1 (2)2 (5)1 (2)1 (2)0.571Neutropenia10 (23)2 (5)7 (16)3 (7)1 (2)0.660Febrile neutropenia01 (2)1.000Anemia35 (81)1 (2)34 (79)1 (2)0.787Thrombocytopenia9 (21)8 (19)1 (2)0.787Leucopenia6 (14)2 (5)6 (14)1 (2)1.000Increased LFT15 (35)1 (2)11 (26)0.348*AE* adverse event; *Gr* grade; *N* number, *LFT* liver function test^a^significant difference between two groups

Discussion {#Sec13}
==========

This randomized phase II study was designed to evaluate the effect of intercalation therapy with gefitinib and paclitaxel/carboplatin chemotherapy as first-line treatment in a clinically selected population, excluding non-smoking patients with adenocarcinoma or patients with wild-type EGFR. Our study demonstrated that gefitinib intercalation did not improve the efficacy of paclitaxel/carboplatin chemotherapy in relation to ORR, PFS, and OS. Toxicity profiles were generally clinically tolerable. Combination treatment resulted in more frequent skin toxicity.

Earlier studies that assessed the combination of chemotherapy and EGFR TKIs failed to show a survival advantage. In two randomized studies, the addition of daily gefitinib or erlotinib to standard chemotherapy did not improve OS, time to progression or ORR compared with chemotherapy alone \[[@CR9]--[@CR11]\].

Two possible combination approaches have been proposed to solve this problem: a pure sequential strategy, in which chemotherapy is followed by maintenance EGFR TKI treatment \[[@CR18], [@CR19]\], and an intercalated administration strategy based on cell cycle-dependent cytotoxicity, which was supported by the results of preclinical and preliminary clinical studies \[[@CR12]--[@CR16]\].

One preclinical study assessed the effects of sequential administration of pemetrexed and erlotinib, and showed cytotoxic synergism in both mutant and wild-type EGFR cell lines \[[@CR12]\]. In another preclinical study, the sequence-dependent synergism between paclitaxel and gefitinib was demonstrated in human lung cancer cell lines with both wild-type and mutant EGFR genes \[[@CR13]\]. Several later phase I/II clinical studies showed that an intercalated regimen of chemotherapy and EGFR TKI is safe and effective \[[@CR14]--[@CR16], [@CR20]\].

Recently, two clinical studies reported that the intercalated regimen offered superior efficacy compared to chemotherapy or EGFR TKIs alone \[[@CR21], [@CR22]\]. In the First-line Asian Sequential Tarceva and Chemotherapy Trial (FASTACT)-2, intercalated therapy with gemcitabine plus platinum and erlotinib improved OS and PFS compared to chemotherapy alone for unselected patients with advanced stage NSCLC as first-line setting. In subset analyses, patients with wild-type EGFR did not benefit from this intercalated regimen. \[[@CR21]\] In a three-arm phase II study, pemetrexed-erlotinib improved PFS compared to either drug alone in a clinically selected population of never-smoking patients with non-squamous NSCLC as second-line therapy \[[@CR22]\].

Because the combination of chemotherapy and EGFR TKIs showed cytotoxic synergism against wild-type EGFR NSCLC cell lines in a preclinical study \[[@CR12], [@CR13]\] and this combination was suggested as a new treatment option for patients with unknown EGFR status in a previous clinical study \[[@CR21]\], we hypothesized that the intercalated strategy could be effective in patients with wild-type or unknown EGFR status. Despite the results of preclinical and clinical studies, our study failed to show the efficacy of intercalated therapy in patients with wild-type EGFR or in a clinically selected population that excluded non-smoking patients with adenocarcinoma. Although molecular tests are used routinely in clinical practice, EGFR status remains unknown in certain patients. The negative result of the present study was consistent with the results of Matjaz Zwitter et al.'s study, which showed that intercalated treatment was not of benefit for EGFR wild-type NSCLC \[[@CR23]\].

On the other hand, intercalated treatment might be a promising approach for patients with NSCLC with EGFR mutant disease or selected patient with unknown EGFR mutation status, according to several clinical studies \[[@CR21]--[@CR23]\]. There were some explanations for the high efficacy of the intercalated therapy, including synergism of different categories of drugs and preventing repopulation of the tumor. However, a randomized trial comparing intercalated therapy with sequential treatment is needed to confirm the real value of intercalated therapy for EGFR mutated NSCLC.

Conclusions {#Sec14}
===========

In conclusion, the results of the present study indicated that intercalated treatment with chemotherapy and EGFR TKIs does not improve ORR, PFS, and OS compared to chemotherapy alone in patients in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR.
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